{"date":"2026-08-16","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6446-2026-08-16-1134-32qmhv","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2026-08-16","time":"11:34:40","subject":"本公司向衛福部食藥署（TFDA）申請變更Ropeginterferonalfa-2b（P1101）ET適應症為治療所有ET成人病人及PV適應症用法用量為高劑量給藥方案","clause":"第10款","fact_date":"2026-08-14","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2026-08-16 11:34，「本公司向衛福部食藥署（TFDA）申請變更Ropeginterferonalfa-2b（P1101）ET適應症為治療所有E」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}